Clinical Observation of the Efficacy and Safety of Risperidone Long-Acting Injection (Risperdal Consta) in the Treatment of Schizophrenia in China

Trial Profile

Clinical Observation of the Efficacy and Safety of Risperidone Long-Acting Injection (Risperdal Consta) in the Treatment of Schizophrenia in China

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 25 Jun 2014

At a glance

  • Drugs Risperidone (Primary) ; Antipsychotics; Benzodiazepines; Serotonin uptake inhibitors
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Xian-Janssen
  • Most Recent Events

    • 13 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top